Beam Therapeutics Inc. (BEAM)
BEAM moved a median of -0.08% 30 minutes after news, and -0.54% by the close. How BEAM actually reacts to news — the realized, point-in-time move the market made, measured across 338 labeled events over the last three years with zero look-ahead.
BEAM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.03% | 46% | 336 |
| 30-min | -0.08% | 47% | 336 |
| 60-min | -0.16% | 49% | 336 |
| to close | -0.54% | 46% | 336 |
| Middle 50% of BEAM reactions | -1.65% to +0.97% |
|---|---|
| Median reaction (30-min) | -0.08% |
| Measured reactions | 338 |
Half of all Beam Therapeutics Inc. news events land between -1.65% and +0.97% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BEAM reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 33 | -0.98% | 24% | +0.43% |
| Analyst downgrades | 14 | -0.03% | 43% | 0.00% |
| Coverage initiations | 19 | +2.02% | 68% | +0.84% |
| Rating reiterations | 75 | -0.27% | 43% | -0.11% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how BEAM ranks against every other measured name →
That’s how BEAM usually reacts — get an email when it moves on news →Email me when BEAM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BEAM's baseline. Nothing else.
Recent BEAM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress | Press release | GlobeNewswire | -0.58% | -1.81% | |
| BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law | Press release | Business Wire | -0.06% | +1.61% | |
| Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | Press release | GlobeNewswire | -3.06% | +0.11% | |
| Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer | Press release | GlobeNewswire | +2.25% | +0.69% | |
| Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences | Press release | GlobeNewswire | -1.09% | +2.01% | |
| Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Press release | GlobeNewswire | +0.43% | +6.06% | |
| Form 10-Q Beam Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.43% | +6.06% | |
| Form 8-K Beam Therapeutics Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +0.43% | +6.06% | |
| Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 | Press release | GlobeNewswire | +1.81% | -0.35% | |
| Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration | Press release | GlobeNewswire | +0.24% | +1.67% | |
| Form 8-K Beam Therapeutics Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +1.17% | -1.07% | |
| Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference | Press release | GlobeNewswire | -1.46% | -1.20% | |
| Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 | Press release | PR Newswire | -0.06% | -0.03% | |
| Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference | Press release | GlobeNewswire | +1.03% | +2.74% | |
| Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026 | Press release | GlobeNewswire | +0.40% | +0.60% | |
| Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates | Press release | GlobeNewswire | +1.42% | -0.79% | |
| Form 10-Q Beam Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.42% | -0.79% | |
| Form 8-K Beam Therapeutics Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +1.42% | -0.79% | |
| Form ARS Beam Therapeutics Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.42% | +0.19% | |
| Form DEF 14A Beam Therapeutics Inc. For: Jun 03 | SEC filing · Form DEF | SEC EDGAR | +0.42% | +0.19% | |
| Form DEFA14A Beam Therapeutics Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.42% | +0.19% | |
| Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine | Press release | GlobeNewswire | +1.89% | +4.85% | |
| Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Press release | GlobeNewswire | -0.49% | -5.09% | |
| Form 8-K Beam Therapeutics Inc. For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +3.93% | +7.41% | |
| Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street | Press release | GlobeNewswire | +3.63% | +8.54% | |
| Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) | Press release | GlobeNewswire | +3.63% | +8.54% | |
| Form 10-K Beam Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.63% | +8.54% | |
| Form 8-K Beam Therapeutics Inc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +3.63% | +8.54% | |
| Form S-8 Beam Therapeutics Inc. | SEC filing · Form S-8 | SEC EDGAR | +3.63% | +8.54% | |
| Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program | Press release | GlobeNewswire | +3.63% | +8.54% | |
| Form 8-K Beam Therapeutics Inc. For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | +3.82% | +0.98% | |
| Form 8-K Beam Therapeutics Inc. For: Jan 31 | SEC filing · Form 8-K | SEC EDGAR | +2.22% | +3.47% | |
| Form 8-K Beam Therapeutics Inc. For: Jan 11 | SEC filing · Form 8-K | SEC EDGAR | +6.35% | +14.40% | |
| Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition | Press release | GlobeNewswire | +6.35% | +14.40% | |
| Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.06% | +0.83% | |
| Form 8-K Beam Therapeutics Inc. For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | -0.61% | -1.05% | |
| Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions | Press release | PR Newswire | +0.04% | -2.25% | |
| Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting | Press release | GlobeNewswire | +0.22% | -1.63% | |
| Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference | Press release | GlobeNewswire | +1.31% | -1.44% | |
| Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates | Press release | GlobeNewswire | +1.49% | -1.64% | |
| Form 10-Q Beam Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.49% | -1.64% | |
| Form 8-K Beam Therapeutics Inc. For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +1.49% | -1.64% | |
| Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting | Press release | GlobeNewswire | +0.45% | -1.70% | |
| Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences | Press release | GlobeNewswire | -0.63% | -1.97% | |
| Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | Press release | GlobeNewswire | +2.06% | -0.68% | |
| Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) | Press release | GlobeNewswire | -3.99% | -1.79% | |
| Form 10-Q Beam Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.99% | -1.79% | |
| Form 8-K Beam Therapeutics Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -3.99% | -1.79% | |
| Form 8-K Beam Therapeutics Inc. For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | -0.73% | -3.13% | |
| Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Press release | GlobeNewswire | +1.67% | +0.95% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BEAM section they belong to.
Where else BEAM is measured.
BEAM earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Beam Therapeutics Inc.'s median reaction calculated?
Every labeled BEAM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 338 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of BEAM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BEAM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.